Lu Wang, MD, PhD

Lu Wang, MD, PhD

I am a geneticist with expertise in clinical molecular genetics and clinical cytogenetics. My primary specialty is the use of molecular cytogenetics and molecular pathology to diagnose cancer.

Molecular cytogenetics is a continually expanding field due to the rapid progress in cancer genetics research. I closely monitor the new diagnostic and prognostic markers emerging from translational research in order to promptly develop the needed assays for clinical testing of patients.

My investigative research in cancer genetics involves the detection and cloning of new recurrent genomic rearrangements in human cancers. The goal of my work is to identify novel pathogenic molecules that can be used for genetic diagnosis of cancer and lead to improvement in the care of cancer patients.

Location
Phone
212-639-5287
Clinical Expertise

Clinical Molecular Genetics and Cancer Cytogenetics

Languages Spoken
English
Education

MD, Shandong University School of Medicine (China); PhD, Shanghai Institute of Hematology, Shanghai Second Medical University (China)

Fellowships

Weill Cornell Medical College; Memorial Sloan Kettering Cancer Center

Board Certifications

Clinical Molecular Genetics

Publications by Lu Wang

Wang L, Motoi T, Khanin R, Olshen A, Mertens F, Bridge J,  Dal Cin P, Antonescu C, Singer S, Hameed M, Bovee J, Hogendoorn P.C.W., Socci N, Ladanyi M. Identification of a Novel, Recurrent HEY1-NCOA2 Fusion in Mesenchymal Chondrosarcoma based on a Genome-wide Screen of Exon-level Expression Data. Genes Chromosomes & Cancer. 2012 Feb;51(2):127-39.

Chmielecki J, Foo J, Oxnard GR, Hutchinson K, Ohashi K, Somwar R, Wang L, Amato KR, Arcila M, Sos ML, Socci ND, Viale A, de Stanchina E, Ginsberg MS, Thomas RK, Kris MG, Inoue A, Ladanyi M, Miller VA, Michor F, Pao W. Optimization of Dosing for EGFR-Mutant Non-Small Cell Lung Cancer with Evolutionary Cancer Modeling. Sci Transl Med. 2011 Jul 6;3(90):90ra59.

Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L, Creaney J, Lake RA, Zakowski MF, Reva B, Sander C, Delsite R, Powell S, Zhou Q, Shen R, Olshen A, Rusch V, Ladanyi M. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet. 2011 Jun 5;43(7):668-72.

Yaming Qiao, Lu Wang, Li-Qun Cai, Chen Tan, Julianne Imperato-McGinley, Yuan-Shan Zhu. . Inhibition of Aberrant Androgen Receptor Induction of Prostate Specific Antigen Gene Expression, Cell Proliferation and Tumor Growth by 17a-Estradiol in Prostate Cancer Cases.. Journal of Andrology January 1, 2011; 185(1) :305-14

Ozawa T, Brennan CW, Wang L, Squatrito M, Sasayama T, Nakada M, Huse JT, Pedraza A, Utsuki S, Yasui Y, Tandon A, Fomchenko EI, Oka H, Levine RL, Fujii K, Ladanyi M, Holland EC. PDGFRA gene rearrangements are frequent genetic events in PDGFRA-amplified glioblastomas. Genes & Development. 2010 Oct 1;24(19):2205-18.

Chitale D, Gong Y, Taylor BS, Broderick S, Brennan C, Somwar R, Golas B, Wang L, Motoi N, Szoke J, Reinersman JM, Major J, Sander C, Seshan EV, Zakowski MF, Rusch V, Pao W, Gerald W, Ladanyi M. An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors. Oncogene. 2009 Aug 6;28(31):2773-83.